Agios Pharmaceuticals Inc. has announced a strategic partnership with Avanzanite Bioscience B.V., a specialty pharmaceutical company focused on rare disease medicines in Europe. The agreement grants Avanzanite the commercialization and distribution rights for PYRUKYND® (mitapivat), a pyruvate kinase activator approved for adults with PK deficiency, across the European Economic Area, the UK, and Switzerland. This partnership aims to enhance patient access to rare disease therapies without the need for costly local infrastructure. Avanzanite plans to expand into 32 European countries over the next year, continuing its mission to ensure no patient is left behind.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agios Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250609510947) on June 09, 2025, and is solely responsible for the information contained therein.